Here are the 424B prospectus supplements from IceCure Medical Ltd. (ICCM) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ICCM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICCM filings page.
IceCure Medical Ltd. is offering up to $4,339,697 of Ordinary Shares in an at‑the‑market offering under a Sales Agreement with A.G.P./Alliance Global Partners dated May 12, 2026. Sales may occur from time to time on Nasdaq or by other lawful methods. A.G.P. will act as sales agent or principal for sales and will receive a fixed commission of 3.0% of gross sales; there is no escrow arrangement. The company reported 81,237,799 Ordinary Shares outstanding as of May 8, 2026. The prospectus supplement notes a March 2026 registered direct offering that sold 8,000,000 Ordinary Shares at $0.50 per share and generated gross proceeds of approximately $4.0 million, together with Series B and Series C warrants exercisable at $0.55. The net proceeds from this ATM program are intended for working capital and general corporate purposes.
The company is offering 8,000,000 Ordinary Shares in a registered direct offering at a combined purchase price of $0.50 per Ordinary Share together with privately placed Series B and Series C warrants.
The offering includes a concurrent private placement of up to 16,000,000 Warrants (8,000,000 Series B Warrants and 8,000,000 Series C Warrants) exercisable at $0.55 per share. Net proceeds are estimated at approximately $3.5 million, intended for working capital and general corporate purposes.